Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Prostate SPOREs

Prostate cancer (PrCa) is the most diagnosed cancer in men. In 2024, there is an estimated 299,010 new cases and 35,250 deaths for the United States. The highest incidence is found in Black men. Black men account for 186.1 cases per 100,000 versus 88.6 per 100,000 in other populations averaged. The percent of patients surviving for 5 years is 97% for local and regional disease and 37% for metastatic disease.

The current PrCa Specialized Programs of Research Excellence (SPOREs) are highly collaborative translational research teams, sharing resources and conducting inter-institutional clinical studies for the prevention, monitoring, and treatment of PrCa. Translational research projects within the prostate SPOREs explore blood and urine biomarkers for risk stratification, germline genetic variants to predict aggressive cancers, the molecular evolution of resistance to androgen deprivation therapies and the development of neuroendocrine prostate cancer, and cellular mechanisms involved in metastatic PrCa. Novel therapeutics are being developed that target the androgen receptor pathway inhibition and DNA damage repair and epigenetic pathways. Immunotherapeutic approaches as well as therapies targeting the tumor microenvironment and many other cellular pathways are also being developed.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Prostate SPOREs was originally published by the National Cancer Institute.”

Email